News

1st Colonial Bancorp, Inc. Reveals Strong Financial Growth

1st Colonial Bancorp, Inc. Reveals Strong Financial Growth

1st Colonial Bancorp, Inc. Financial Overview

1st Colonial Bancorp, Inc. (FCOB), parent company of 1st Colonial Community Bank, has reported impressive financial results for the fourth quarter of 2024. The bank achieved a net income of $2.7 million, translating to $0.55 per diluted share, which marks an increase from $2.1 million or $0.44 per diluted share in the same period last year. Throughout the year, net income reached $8.1 million, or $1.64 per diluted share, compared to $7.4 million, or $1.54 per diluted share, for the previous year.

Key Financial Highlights

Profitability and Income Growth

Robert White, President and CEO, expressed satisfaction with the 2024 results, emphasizing the bank's unwavering focus on profitability and operational efficiency. The company witnessed notable growth in non-interest income, driven primarily by advancements in its residential mortgage division. This quarter saw ongoing momentum in both residential and consumer lending, indicating a positive outlook as 2025 approaches.

Deposit Growth and Competitive Rates

The fourth quarter showcased robust deposit growth, encouraged by the bank's commitment to offering exceptional financial products and services, coupled with attractive deposit rates. The enhanced net interest margin of 3.29% for this quarter signifies a continued positive trend that is anticipated to persist into the new year. White noted a renewed market enthusiasm and a robust increase in the commercial lending pipeline, supporting client business growth.

Operational Performance Insights

Net Interest Income Analysis

For the last quarter of 2024, net interest income stood at $6.6 million, up from $6.3 million in 2023. This increase was mainly due to rising interest income on average interest-earning assets, surpassing the increase in interest expenses on liabilities.

The average yield on interest-earning assets observed an upward shift, ascending from 5.30% in the previous year to 5.38% in 2024's fourth quarter. Furthermore, the average interest-bearing liabilities rate increased slightly from 2.41% to 2.49% year-over-year. Looking ahead, the bank anticipates further stability in these rates alongside potential growth in lending.

Loan and Deposit Trends

In 2024, total net interest income was reported at $25.0 million, although this represented a decline from $26.3 million in 2023. Notably, the uptick in interest income from loans and investments partially offset the increase in interest expenses. Average loan balances experienced fluctuations, yet the yield on loans maintained a favorable average of 5.91% throughout the year. This dynamic underscores the bank's resilience in efficiently managing its interest income despite broader economic challenges.

Asset Quality and Financial Position

Loan Portfolio Review

As of December 31, 2024, total loans were recorded at $622.5 million, reflecting a slight decrease compared to the previous year. However, the bank saw significant increases in key areas such as average commercial and residential loans. This shift signifies an appropriate response to customer demand while adhering to prudent lending practices.

Financial Statement Summary

With total assets reaching $841.5 million, a year-over-year increase of 3% was logged. The solid foundation of total deposits at $747.7 million, boosted by strategic marketing efforts aiming to enhance customer relations, illustrates robust growth in the bank's operational scale and profitability.

Looking Forward

1st Colonial plans to invest further in talent and technology as part of its strategic objectives for 2025 and beyond. The bank is fortifying its operational framework to ensure sustained growth while navigating through an evolving financial landscape.

Frequently Asked Questions

What key financial results did 1st Colonial Bancorp report for Q4 2024?

1st Colonial Bancorp reported a net income of $2.7 million, or $0.55 per diluted share, marking an improvement from the previous year.

How did the company's net interest income compare to the previous year?

Net interest income for Q4 2024 was $6.6 million, a slight increase from $6.3 million in Q4 2023.

What are the main drivers of profit growth for the company?

The primary drivers include improved growth in residential mortgages and consumer lending, alongside a strategic commitment to competitive deposit rates.

How did the bank's loan portfolio perform in 2024?

The total loans decreased slightly to $622.5 million, with increases in commercial and residential loans highlighting a solid lending performance.

What are 1st Colonial Bancorp's plans for 2025?

The bank aims to invest in talent and technology to enhance its operational capabilities and continue profitable growth.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 23

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 32

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kotak Mahindra Bank's Innovative Tech Strategies

Updated Category News Views 587

Kotak Mahindra Bank's Commitment to Digital Transformation Kotak Mahindra Bank is at the forefront of revolutionizing financial services through its innovative technology strategies. Their latest report dives deep into the bank's extensive tech activities, highlighting how it leverages digital transformation to enhance customer experience and streamline operations....

Continue Reading
Star Group, L.P. Reflects on Fiscal 2024 Performance Updates

Updated Category News Views 349

Star Group's Fiscal 2024 Insights and Performance Analysis As the fiscal year wraps up, Star Group, L.P. (NYSE: SGU), a respected home energy distributor, shares its financial performance that ended on September 30, 2024. Amidst the prevailing challenges in the energy market, the company continues its commitment to delivering quality services while adapting to market...

Continue Reading
Krystal Biotech Launches Clinical Trial for Eye Therapy KB801

Updated Category News Views 148

Krystal Biotech Begins Phase 1/2 Trial of KB801 Krystal Biotech, Inc. (NASDAQ: KRYS) has recently announced exciting developments in its ophthalmology pipeline with the initiation of a Phase 1/2 clinical trial for KB801, aimed at treating neurotrophic keratitis (NK). This 2:1 randomized, double-masked, multicenter, placebo-controlled study, named EMERALD-1, marks a...

Continue Reading
Key Updates on the Annual General Meeting of Ignitis Group

Updated Category News Views 163

Exciting Updates for the Ignitis Group Shareholders The retained earnings figure for AB “Ignitis grup?” has been amended for the upcoming Annual General Meeting. It now stands at EUR 320,319,368.41, following a revision made only to the English version of the document. This adjustment reflects the company’s commitment to transparency and accuracy in their financial...

Continue Reading
Transforming Connectivity: The Future of mmWave Sensors Growth

Updated Category News Views 104

The mmWave sensors market was set on a blistering growth path back in 2023, valued at around USD 0.25 billion. By the time you fast-forward to 2032, projections had it skyrocketing to USD 2.40 billion, boasting a staggering CAGR of 28.59% from 2024 through 2032. You'd think this kind of momentum would have traders buzzing—oh wait, they were, especially as the push for...

Continue Reading